> I'll add that my own experience of licensing (my own) IP from a top-25 university TTO has been interesting In my experience, there's a lot of variance betwee

> I'll add that my own experience of licensing (my own) IP from a top-25 university TTO has been interesting In my experience, there's a lot of variance between universities, and even between tech transfer officers within a given university. Another complication: at Harvard/MIT, where professors may have cross-institutional appointments, you need to nail down exactly who you'll be dealing with (for example, the Broad has their own TTO: https://www.broadinstitute.org/osap https://www.broadinstitute.org/osap). There are also other issues, such as IIAs & CRADAs. > What were your thoughts on the whole "cult of the molecule" thing from the interview? As you said, it fails to take into account existing attempts to form partnerships by biotech VCs: - http://lifescivc.com/2014/04/pushing-forward-with-collaborative-rd-models-in-biotech-roche-spero-and-biogen-ataxion/ http://lifescivc.com/2014/04/pushing-forward-with-collaborat... - http://www.bizjournals.com/seattle/blog/techflash/2014/01/a-new-approach-to-biotech-investing.html http://www.bizjournals.com/seattle/blog/techflash/2014/01/a-... This is one of those situations where presumption of stupidity (http://www.aaronkharris.com/presumption-of-stupitidy http://www.aaronkharris.com/presumption-of-stupitidy) can be very tempting, given the magnitude of the problems that remain unsolved in the biosciences. It can also take quite a bit of digging to find this info - it's not splashed all over the front page of TechCrunch, like the latest batch of YC startups are.